Europe Skin Cancer Diagnostics Market Size, Share & Trends Analysis Report By Type (Non-Melanoma and Melanoma), By Test Type (Skin Biopsy, Imaging Tests, Dermatoscopy, Lymph Node Biopsy, and Others), By End-use, By Country and Growth Forecast, 2024 - 2031

Europe Skin Cancer Diagnostics Market Size, Share & Trends Analysis Report By Type (Non-Melanoma and Melanoma), By Test Type (Skin Biopsy, Imaging Tests, Dermatoscopy, Lymph Node Biopsy, and Others), By End-use, By Country and Growth Forecast, 2024 - 2031

The Europe Skin Cancer Diagnostics Market would witness market growth of 5.0% CAGR during the forecast period (2024-2031).

The Germany market dominated the Europe Skin Cancer Diagnostics Market by Country in 2023, and would continue to be a dominant market till 2031; thereby, achieving a market value of $895.1 million by 2031. The UK market is exhibiting a CAGR of 4.1% during (2024 - 2031). Additionally, The France market would exhibit a CAGR of 5.9% during (2024 - 2031).

The rising incidence of skin cancer is a central driver of the market. The direct DNA damage that UV radiation causes in skin cells is a well-established risk factor for skin cancer, which can result in malignant transformations. Demographic trends also significantly influence the growing demand for skin cancer diagnostics.

Additionally, Consequently, the aging population is more susceptible to both melanoma and non-melanoma skin cancers, necessitating more frequent and sophisticated diagnostic interventions.

The risk of developing skin cancer demonstrably increases with age. Cumulative sun exposure throughout a lifetime plays a major role. As the European population ages, a greater number of individuals are inherently more susceptible to skin cancer. The demand for skin cancer diagnostics in the United Kingdom is increasing significantly due to an aging population. Non-melanoma skin cancer incidence rates are projected to rise by 14% from 2023-2025 to 2038-2040, reaching 310 cases per 100,000 people annually by 2038-2040.

Based on Type, the market is segmented into Non-Melanoma and Melanoma. Based on Test Type, the market is segmented into Skin Biopsy, Imaging Tests, Dermatoscopy, Lymph Node Biopsy, and Others. Based on End-use, the market is segmented into Hospital & Clinics, Laboratories, and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.

List of Key Companies Profiled

• Castle Biosciences, Inc.
• Bausch Health Companies, Inc. (DermTech, Inc.)
• Canfield Scientific, Inc.
• DermaSensor, Inc.
• F. Hoffmann-La Roche Ltd.
• NeoGenomics, Inc.
• Quest Diagnostics Incorporated.
• Digital Diagnostics, Inc. (3Derm Systems, Inc.)
• FotoFinder Systems GmbH
• Veriskin Inc

Europe Skin Cancer Diagnostics Market Report Segmentation

By Type

• Non-Melanoma
• Melanoma

By Test Type

• Skin Biopsy
• Imaging Tests
• Dermatoscopy
• Lymph Node Biopsy
• Others

By End-use

• Hospital & Clinics
• Laboratories
• Others

By Country

• Germany
• UK
• France
• Russia
• Spain
• Italy
• Rest of Europe